Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Refractory Mantle Cell Lymphoma Clinical Trial

Official title:

A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04703686
• Other study ID #: BiCAR
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: March 30, 2021
• Est. completion date: March 1, 2026

Study information

• Verified date: December 2023
• Source: The Lymphoma Academic Research Organisation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a multicenter phase II trial including 2 cohorts of patients in Refractory/Relapse disease at least 1 month after CAR T-cells therapy:

• cohort 1: DLBCL patients

• cohort 2: PMBL, mantle cell lymphoma, transformed indolent NHL (t-iNHL) or iNHL CAR T-cells Refractory/Relapse status will be determined by PET-CT central review allowing inclusion in this trial.

Patients enrolled will then receive a pre-phase of obinutuzumab followed by experimental treatment:11 cycle of glofitamab.

The primary objective of the study is to assess the anti-lymphoma activity of glofitamab, a bispecific CD3xCD20 monoclonal antibody in patients with relapse/refractory DLBCL (cohort 1) disease after anti-CD19 CAR T-cells therapy

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 67
• Est. completion date: March 1, 2026
• Est. primary completion date: January 10, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients who received CAR T-cells therapy for R/R DLBCL (cohort 1) or R/R PMBL, mantle cell lymphoma, t-iNHL or iNHL (cohort 2), at least 1 month ago

2. Patients who are not, at least in partial metabolic response from 1 month after CAR T-cells infusion (i.e no metabolic response or first metabolic progressive disease or first relapse from 1 month after CAR T-cells infusion)

3. First metabolic progression, first relapse or no metabolic response after CAR T-cells infusion must be confirmed by PET-CT central review for enrollment

4. DLBCL with demonstrated lymphoma cells-expressing CD20 at relapse post CAR T-cells as demonstrated by biopsy before enrollment (cohort 1 only)

5. Aged 18 years or more with no upper age limit

6. ECOG performance status 0 or 1

7. Bi-dimensionally measurable disease defined by at least one single node or tumor lesion > 1.5 cm assessed by CT scan, or PET-CT with at least one hypermetabolic lesion

8. No persistant CAR-T neurotoxicity symptoms or previous experience during CAR T-cells therapy of neurotoxicity grade > 3

9. Adverse events from prior anti-cancer therapy must have resolved to Grade = 1 (hematological toxicities excepted)

10. Adequate liver function: Total bilirubin = 1.5 x ULN; Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) = 3 x ULN Note: Patients with documented history of Gilbert's Syndrome and in whom total bilirubin elevations are accompanied by elevated indirect bilirubin are eligible)

11. Adequate hematological function: Neutrophil count of = 1.0 G/L; Platelet count of = 50 G/L (and platelet transfusion free within 14 days prior to administration of obinutuzumab); Hemoglobin (Hb) = 8.0 g/dL (transfusion free within 21 days prior to administration of obinutuzumab) Note: patients who do not meet the above hematologic criteria, due to extensive tumor involvement in the marrow may be enrolled into the trial after the demonstration of involvement and consultation with the LYSARC. Please consult the LYSARC on the need for transfusion support within 21 days of obinutuzumab

12. Adequate renal function: creatinine clearance (CrCl) calculated by MDRD/cockcroft -Gault formula of = 30 mL/min

13. Negative serum or urinary pregnancy test within 7 days prior to study treatment in women of childbearing potential

14. Negative serologic or PCR test results for acute or chronic HBV infection Note:

Patients whose HBV infection status cannot be determined by serologic test results must be negative for HBV by PCR to be eligible for study participation

15. Negative test results for HCV and HIV Note: Patients who are positive for HCV antibody must be negative for HCV by PCR to be eligible for study participation

16. Patients must agree to either remain completely abstinent or to use two effective contraceptive methods* until:

• If the patient is a male: at least 3 months after pre-treatment with obinutuzumab or 2 months after the last dose of glofitamab, whichever is longer, Men must refrain from donating sperm during this same period

• If patient is a female of childbearing potential: until at least 18 months after pre-treatment with obinutuzumab or 2 months after the last dose of glofitamab, whichever is longer

17. Patient must be willing and able to comply with protocol-mandated hospitalization upon administration of the first dose of glofitamab. Patient must also be willing to comply with all study-related procedures.

18. Signed written informed consent

19. Life expectancy = 3 months

20. Patient covered by any social security system

21. Patient who understands and speaks one of the country official languages

Exclusion Criteria:

1. Previously known CD20 negative status, excepted if a new biopsy for cohort 1 or biopsy or cytometry analysis for cohort 2 proving a CD20 positive status is available before enrollment

2. Patients with CLL, Richter and Burkitt lymphoma

3. Patients relapsing or progressing within 1 months (30 days) after CAR T-cells therapy

4. History of treatment-emergent immune-related adverse events associated with prior immunotherapeutic agents, as follows:

• Grade = 3 adverse events with the exception of Grade 3 endocrinopathy managed with replacement therapy

• Grade 1-2 adverse events that did not resolve to baseline after treatment discontinuation

5. Current or past history of detectable cerebrospinal fluid lymphoma cells, or with a history of CNS lymphoma localization or primary CNS lymphoma

6. Current or past history of cerebral disorders

7. Any serious psychiatric illness that would prevent the subject from signing the informed consent form.

8. Patients with history of macrophage activation syndrome (MAS) / hemophagocytic lymphohistiocytosis (HLH)

9. Patients with known acute infection or reactivation of a latent infection, whether bacterial, viral (including, but not limited to, EBV, cytomegalovirus (CMV), hepatitis B, hepatitis C, and HIV), fungal, mycobacterial, or other pathogens (excluding fungal infections of nail beds) or any major episode of infection requiring hospitalization or treatment with IV antibiotics (for IV antibiotics this pertains to completion of last course of antibiotic treatment) in 2 week prior to enrollment

10. LVEF < 40% as determined by echocardiography or multiple uptake gated acquisition (MUGA) scan or significant cardiovascular disease such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina)

11. Any serious active disease or co-morbid medical condition

12. Clinically significant history of liver disease or cirrhosis

13. Prior history of malignancies other than lymphoma unless the subject has been free of the disease for = 3 years. Exceptions will be allowed for patients with non-melanoma skin tumors (basal cell or squamous cell carcinoma of the skin) or any surgically removed stage 0 (in situ) carcinoma

14. Prior solid organ transplantation

15. Prior allogeneic SCT

16. Autologous SCT within 100 days prior to obinutuzumab infusion

17. Current uncontrolled autoimmune disease Note: History of autoimmune disease currently controlled and stable is acceptable for such therapy. See detailed description below*

18. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug

19. Major surgery or significant traumatic injury < 28 days prior to the obinutuzumab infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment

20. Administration of a live, attenuated vaccine within 4 weeks before obinutuzumab infusion

21. Treatment between infusion of CAR T-cells and pre-phase (i.e. obinutuzumab infusion on C1/D-3): with standard radiotherapy, systemic immunotherapeutic agents, any chemotherapeutic agent, any systemic immunosuppressive medications or treatment with any other investigational anti-cancer agent (defined as treatment for which there is currently no regulatory authority approved indication) Note: with the exception of corticosteroid treatment < 25 mg/day prednisone or equivalent. Inhaled and topical steroids are permitted

22. Patient with history of confirmed progressive multifocal leukoencephalopathy (PML)

23. History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)

24. History of illicit drug or alcohol abuse within 12 months prior to enrollment

25. Person deprived of his/her liberty by a judicial or administrative decision

26. Inability to comply with protocol mandated hospitalization and restrictions

27. Adult person under legal protection

28. Adult person unable to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness

29. Pregnant or breast-feeding or intending to become pregnant during the study

Related Conditions & MeSH terms

• Diffuse Large B-Cell Lymphoma Refractory
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Large B-Cell, Diffuse
• Lymphoma, Mantle-Cell
• Lymphoma, Non-Hodgkin
• Refractory Indolent Adult Non-Hodgkin Lymphoma
• Refractory Mantle Cell Lymphoma
• Refractory Primary Mediastinal Large B-Cell Cell Lymphoma
• Refractory Transformed B-cell Non-Hodgkin Lymphoma

Intervention

Drug:
• Obinutuzumab
1000mg - prephase - one infusion at D-3
• RO7082859
2.5 mg D1C1, 10 mg D3C1, then 30 mg D8C1 and D1 every 21 days (C2-C11, D1C2 starts 14 days after D1C1)

Locations

Country	Name	City	State
France	CHU de Clermont Ferrand	Clermont Ferrand
France	Hopital Henri Mondor	Créteil
France	CHU de Dijon - Hôpital le Bocage	Dijon
France	CHRU Lille - Hôpital Claude Huriez	Lille
France	CHU Montpellier	Montpellier
France	CHU Nantes	Nantes
France	APHP - Hôpital de la Pitiè Salpetrière	Paris
France	APHP - Hôpital Saint Antoine	Paris
France	Hôpital Saint Louis	Paris
France	CHU de Bordeaux - Hôpital Haut Leveque	Pessac
France	CHU Lyon Sud	Pierre Bénite
France	CHU de Rennes - Hôpital Pontchaillou	Rennes
France	Centre Henri Becquerel	Rouen
France	IUCT Oncopole	Toulouse
France	CHU de Brabois	Vandoeuvre les Nancy

Sponsors (1)

Lead Sponsor	Collaborator
The Lymphoma Academic Research Organisation

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival	Overall survival will be measured from the date of C1D1 of glofitamab to the date of death from any cause. Alive patients will be censored at the date of last contact	4 years
Secondary	Metabolic response rates according to Lugano classification	Response will be assessed by local and central review by PET scan according to Lugano classification	At the end of Cycle 2 (1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Metabolic response rates according to Lugano classification	Response will be assessed by local and central review by PET scan according to Lugano classification	At the end of Cycle 6 (1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Metabolic response rates according to Lugano classification	Response will be assessed by local and central review by PET scan according to Lugano classification	At the end of Cycle 9 (1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Metabolic response rates according to Lugano classification	Response will be assessed by local and central review by PET scan according to Lugano classification	At the end of Cycle 11 (1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Progression Free Survival (PFS)	PFS is defined as the time from enrollment into the study to the first observation of documented disease progression based on central review or death due to any cause	At the end of Cycle 2 (1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Progression Free Survival (PFS)	PFS is defined as the time from enrollment into the study to the first observation of documented disease progression based on central review or death due to any cause	At the end of Cycle 4 (1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Progression Free Survival (PFS)	PFS is defined as the time from enrollment into the study to the first observation of documented disease progression based on central review or death due to any cause	At the end of Cycle 6 (1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Progression Free Survival (PFS)	PFS is defined as the time from enrollment into the study to the first observation of documented disease progression based on central review or death due to any cause	At the end of Cycle 9 (1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Progression Free Survival (PFS)	PFS is defined as the time from enrollment into the study to the first observation of documented disease progression based on central review or death due to any cause	At the end of Cycle 11 (1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Duration of Response (DoR)	DoR is defined from the time of first CMR or PMR (according to Lugano criteria) to the date of first documented disease progression, relapse or death from any cause. If a subject has not progressed or died, DoR will be censored at the date of tumor assessment	At the end of Cycle 2 (1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Duration of Response (DoR)	DoR is defined from the time of first CMR or PMR (according to Lugano criteria) to the date of first documented disease progression, relapse or death from any cause. If a subject has not progressed or died, DoR will be censored at the date of tumor assessment	At the end of Cycle 4 (1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Duration of Response (DoR)	DoR is defined from the time of first CMR or PMR (according to Lugano criteria) to the date of first documented disease progression, relapse or death from any cause. If a subject has not progressed or died, DoR will be censored at the date of tumor assessment	At the end of Cycle 6 (1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Duration of Response (DoR)	DoR is defined from the time of first CMR or PMR (according to Lugano criteria) to the date of first documented disease progression, relapse or death from any cause. If a subject has not progressed or died, DoR will be censored at the date of tumor assessment	At the end of Cycle 9 (1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Duration of Response (DoR)	DoR is defined from the time of first CMR or PMR (according to Lugano criteria) to the date of first documented disease progression, relapse or death from any cause. If a subject has not progressed or died, DoR will be censored at the date of tumor assessment	At the end of Cycle 11 (1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Quality of Life - QLQ-C30	Quality of Life scale measurements will be the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30),	at day 1
Secondary	Quality of Life - FACT-Lym LymS	Quality of Life scale measurements will be the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym LymS) subscale	at day 1
Secondary	Quality of Life - QLQ-C30	Quality of Life scale measurements will be the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)	At Cycle 2 Day 1 (1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Quality of Life - FACT-Lym LymS	Quality of Life scale measurements will be the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym LymS) subscale	At Cycle 2 Day 1 (1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Quality of Life - EORTC QLQ-C30	Quality of Life scale measurements will be the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)	At Cycle 3 Day 1(1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Quality of Life _ FACT-Lym LymS	Quality of Life scale measurements will be the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym LymS) subscale	At Cycle 3 Day 1(1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Quality of Life - QLQ-C30	Quality of Life scale measurements will be the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)	At cycle 5 day 1 (1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Quality of Life _ FACT-Lym LymS	Quality of Life scale measurements will be the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym LymS) subscale	At cycle 5 day 1 (1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Quality of Life _ QLQ-C30	Quality of Life scale measurements will be the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)	At Cycle 7 Day 1(1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Quality of Life _ FACT-Lym LymS	Quality of Life scale measurements will be the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym LymS) subscale	At Cycle 7 Day 1 (1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Quality of Life _ QLQ-C30	Quality of Life scale measurements will be the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)	At Cycle 9 Day 1(1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Quality of Life _ FACT-Lym LymS	Quality of Life scale measurements will be the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym LymS) subscale	At Cycle 9 Day 1(1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Quality of Life _ QLQ-C30	Quality of Lifescale measurements will be the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)	At Cycle 11 Day 1(1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Quality of Life _ FACT-Lym LymS	Quality of Life scale measurements will be the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym LymS) subscale	At Cycle 11 Day 1(1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	number of Serious Adverse Events		from the date of first informed consent signature to 30 days after last administration of study drugs
Secondary	Best metabolic response assessed by local review		after 11 cycles (1st cycle of 14 days and subsequent cycles of 21 days)
Secondary	Best metabolic response assessed by central review		after 11 cycles (1st cycle of 14 days and subsequent cycles of 21 days)